Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 2/20 | 0.59 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.50 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | ACACB | O00763 | 1/20 | 0.43 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.42 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
| ▸ | F12 | P00748 | 1/20 | 0.41 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20216030 | 0.86 | ESR2 (0.55) | NR1H2ESR2MAPTKDM4EADORA1 | |
| SCHEMBL16038280 | 0.86 | ESR2 (0.55) | NR1H2ESR2MAPTKDM4EADORA1 | |
| SCHEMBL16039921 | 0.86 | ESR2 (0.58) | NR1H2ESR2MAPTKDM4EADORA1 | |
| SCHEMBL3605554 | 0.85 | NR1H2 (0.62) | NR1H2ESR2MAPTKDM4EADORA1 | |
| SCHEMBL3601184 | 0.84 | NR1H2 (0.60) | NR1H2ESR2MAPTKDM4EADORA1 | |
| SCHEMBL2568433 | 0.83 | ESR2 (0.52) | NR1H2ESR2MAPTKDM4EADORA1 | |
| SCHEMBL30406062 | 0.83 | ESR2 (0.52) | NR1H2ESR2MAPTKDM4EADORA1 | |
| SCHEMBL3600122 | 0.83 | ESR2 (0.52) | NR1H2ESR2MAPTKDM4EADORA1 | |
| SCHEMBL13074439 | 0.83 | ESR2 (0.55) | NR1H2ESR2MAPTKDM4EADORA1 | |
| SCHEMBL3604757 | 0.81 | NR1H2 (0.57) | NR1H2ESR2MAPTKDM4EADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298285-A1 | Biclycloheteroaryl Compounds as P2x7 Modulators and Uses Thereof | RENOVIS, INC. | 2010-11-25 | — | — | US | disclosed |
| US-20100298285-A1 | Biclycloheteroaryl Compounds as P2x7 Modulators and Uses Thereof | RENOVIS, INC. | 2010-11-25 | — | — | US | disclosed |
| US-20100298285-A1 | Biclycloheteroaryl Compounds as P2x7 Modulators and Uses Thereof | RENOVIS, INC. | 2010-11-25 | — | — | US | disclosed |
| WO-2007109182-A2 | BICYCLOHETEROARYL COMPOUNDS AS P2X7 MODULATORS AND USES THEREOF | RENOVIS, INC. (US) | 2007-09-27 | — | — | WO | disclosed |
| WO-2007109182-A2 | BICYCLOHETEROARYL COMPOUNDS AS P2X7 MODULATORS AND USES THEREOF | RENOVIS, INC. (US) | 2007-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298285-A1 | Biclycloheteroaryl Compounds as P2x7 Modulators and Uses Thereof | P2RX7, P2RX3, P2RX1 | NR1H2 176/4885ESR2 1497/4885MAPT 4473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.